Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin Lymphoma focused on measuring non-hodgkins lymphoma, interleukin-2, rituximab, CD20+ follicular B-cell non-hodgkins lymphoma (grade I, II,III)
Eligibility Criteria
Inclusion Criteria: CD20+ follicular B-cell non-hodgkin's lymphoma with at least 1 site of measurable disease. Previous treatment with 1 to 4 prior chemotherapy regimens ECOG performance status of greater than or equal to 2 Life expectancy of greater than 18 weeks Meet safety lab requirements and organ function tests Exclusion Criteria: Prior treatment with rituximab or IL-2 Prior radioimmunotherapy including Zevalin or Bexxar 5 or more prior chemotherapy regimens Clinically significant cardiac disease, lung dysfunction, autoimmune disease, thyroid disease, active infection, unstable psychiatric condition, or HIV infection. History of allogenic bone marrow transplant Female subjects that are pregnant or breast feeding Immunosuppressive therapy including corticosteroids or investigational agents within 4 weeks prior to the planned start of study treatment
Sites / Locations
- Roswell Park Cancer Institute